Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 3, 1996, Pages 1447-1452

  Murray, Michael ^a,b   Butler, Alison M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DILTIAZEM; DILTIAZEM DERIVATIVE; DRUG METABOLITE; TESTOSTERONE;

ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; ENZYME INHIBITION; LIVER METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR; STEROID HYDROXYLASES;

EID: 0030426708     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. ABERNETHY, D. R. AND MONTAMAT, S. C.: Acute and chronic studies of diltiazem in elderly vs. young hypertensive patients. Am. J. Cardiol. 60: 1161-1201, 1987.
2. ASCALONE, V., LOCATELLI, M. AND MALAVASI, B.: Determination of diltiazem and its main metabolites in human plasma by automated solid-phase extraction and high-performance liquid chromatography: A new method overcoming instability of the compounds and interference problems. J. Chromatogr. 657: 133-140, 1994.
3. BAUER, L. A., STENWALL, M., HORN, J. R., DAVIS, R., OPHEIM, K. AND GREENE, L.: Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil and diltiazem therapy. Clin. Pharmacol. Ther. 40: 239-242, 1986.
4. BENSOUSSAN, C., DELAFORGE, M. AND MANSUY, D.: Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem. Pharmacol. 49: 591-602, 1995.
5. BONNEFOUS, J.-L., BOULIEU, R. AND LAHET, C.: Stability of diltiazem and its metabolites in human blood samples. J. Pharm. Sci. 81: 341-344, 1992.
6. BUTLER, A. M. AND MURRAY, M.: Inhibition and inactivation of constitutive cytochromes P450 in rat liver by parathion. Mol. Pharmacol. 43: 902-908, 1993.
7. CARRUM, G., EGAN, J. M. AND ABERNETHY, D. R.: Diltiazem treatment impairs hepatic drug oxidation: Studies of antipyrine. Clin. Pharmacol. Ther. 40: 140-143, 1986.
8. ESTABROOK, R. W. AND WERRINGLOER, J.: The measurement of difference spectra: Application to the cytochromes of microsomes. Methods Enzymol. 52: 212-220, 1978.
9. HOGLUND, P. AND NILSSON, L. G.: Pharmacokinetics of diltiazem and its metabolite after single and multiple dosing in healthy volunteers. Ther. Drug Monit. 11: 558-566, 1989.
10. JEFCOATE, C. R.: Measurement of substrate and inhibitor binding to microsomal cytochrome P450 by optical difference spectroscopy. Methods Enzymol. 52: 258-279, 1978.
11. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
12. MCNEIL, C. M. AND MURRAY, M.: Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites. Biochem. Pharmacol. 51: 15-20, 1996.
13. MONTAMAT, S. C. AND ABERNETHY, D. R.: N-Monodemethyldiltiazem is the predominant metabolite of diltiazem. Br. J. Clin. Pharmacol. 24: 185-189, 1987.
14. MURRAY, M.: Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. Mol. Pharmacol. 42: 931-938, 1992.
15. MURRAY, M., HUDSON, A. M. AND YASSA, V.: Hepatic microsomal metabolism of the anthelmintic benzimidazole fenbendazole: Enhanced inhibition of cytochrome P450 reactions by oxidized metabolites of the drug. Chem. Res. Toxicol. 5: 60-66, 1992.
16. MURRAY, M. AND REIDY, G. F.: Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 42: 85-101, 1990.
17. MURRAY, M., WILKINSON, C. F. AND DUBE, C. E.: Effects of dihydrosafrole on cytochromes P-450 and drug oxidation in hepatic microsomes from control and induced rats. Toxicol. Appl. Pharmacol. 68: 66-76, 1983.
18. NAKAMURA, S., SUGAWARA, Y., FUKUSHIMA, T., ITO, Y., OHASHI, M. AND TAKAITI, O.: Metabolism of clentiazem in rats. Biol. Pharm. Bull. 16: 635-646, 1993.
19. OMURA, T. AND SATO, R.: The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239: 2370-2378, 1964.
20. PICHARD, L., GILLET, G., FABRE, I., DALET-BELUCHE, I., BONFILS, C., THENOT, J.-P. AND MAUREL, P.: Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab. Dispos. 18: 711-719, 1990.
21. PIEPHO, R. W., CULBERTSON, V. L. AND RHODES, R. S.: Drug interactions with the calcium-entry blockers. Circulation 75: V-181-194, 1987.
22. RENTON, K. W.: Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem. Pharmacol. 34: 2549-2553, 1985.
23. SCHLANZ, K. D., MYRE, S. AND BOTTORFF, M. B.: Pharmacokinetic interactions with calcium channel antagonists. I. Clin. Pharmacokinet. 21: 344-356, 1991a.
24. SCHLANZ, K. D., MYRE, S. AND BOTTORFF, M. B.: Pharmacokinetic interactions with calcium channel antagonists. II. Clin. Pharmacokinet. 21: 448-460, 1991b.
25. SEGAL, I.: Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, John Wiley and Sons, New York, 1975.
26. SIRMANS, S. M., PIEPER, J. A., LALONDE, R. L., SMITH, D. G. AND SELF, T. H.: Effect of calcium channel blockers on theophylline disposition. Clin. Pharmacol. Ther. 44: 29-34, 1988.
27. SMITH, C. L., HAMPTON, E. M., PEDERSON, J. A., PENNINGTON, L. R. AND BOURNE, D. W.: Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Pharmacotherapy 14: 471-481, 1994.
28. SUGAWARA, Y., OHASHI, M., NAKAMURA, S., USUKI, S., SUZUKI, T., ITO, Y., KUME, T., HARIGAYA, S., NAKAO, A., GAINO, M. AND INOUE, H.: Metabolism of diltiazem. I. Structures of new acidic and basic metabolites in rat, dog and man. J. Pharmacobio-Dyn. 11: 211-223, 1988.
29. TSAO, S.-C., DICKINSON, T. H. AND ABERNETHY, D. R.: Metabolite inhibition of parent drug biotransformation: Studies of diltiazem. Drug Metab. Dispos. 18: 180-182, 1990.
30. WAXMAN, D. J., DANNAN, G. A. AND GUENGERICH, F. P.: Regulation of rat hepatic cytochrome P-450: Age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry 24: 4409-4417, 1985.
31. WAXMAN, D. J., KO, A. AND WALSH, C.: Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J. Biol. Chem. 258: 11937-11947, 1983.
32. YEUNG, P. K. F., MOSHER, S. J., QUILLIAM, M. A. AND MONTAGUE, T. J.: Species comparison of pharmacokinetics and metabolism of diltiazem in humans, dogs, rabbits, and rats. Drug Metab. Dispos. 18: 1055-1059, 1990.